RECRUITING

Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions

Description

The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.

Conditions

PancreatitisPancreas CancerPancreas Cyst
Talk to us

Related Conditions:

PancreatitisPancreas CancerPancreas Cyst

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.

The Role of Contrast Enhanced Endoscopic Ultrasound for Evaluation of Pancreas Lesions

Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions

Condition
Pancreatitis
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients undergoing endoscopic ultrasound for pancreatic indications
  • * Patients must have unexplained pancreatitis, pancreas mass(es), or pancreatic cystic lesions or worrisome clinical, imaging or laboratory findings
  • * Patients \<18 years of age, pregnant women, and lactating mothers will be excluded.
  • * Subjects with unstable cardiopulmonary condition will be excluded (acute myocardial infarction, acute coronary syndromes, worsening or unstable heart failure, or serious ventricular arrhythmias)
  • * Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts will be excluded given theoretical (though clinically insignificant) risk of embolization
  • * Patients with a history of allergy to Lumason will be excluded

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cedars-Sinai Medical Center,

Srinivas Gaddam, MD, PRINCIPAL_INVESTIGATOR, Cedars-Sinai Medical Center

Study Record Dates

2025-12-31